Home
Alerts
Search
Watchlist
Products
Curis Lifesciences Ltd
CURIS
NSE
₹ 125.00
4.17%
Last Updated:
29 Apr '26, 4:00 PM
Industry:
Pharmaceuticals Bulk Drugs & Formulation
Curis Lifesciences Ltd
CURIS
NSE
₹ 125.00
4.17%
29 Apr '26, 4:00 PM
Industry
Pharmaceuticals Bulk Drugs & Formulation
6M
Price
Charts
Documents
Quick Ratios
Edit Ratios
Mkt Cap
Market Capitalization
₹101Cr
Close
Close Price
₹125.00
Industry
Industry
Pharmaceuticals Bulk Drugs & Formulation
PE
Price To Earnings
16.56
PS
Price To Sales
2.06
Revenue
Revenue
₹49Cr
Rev Gr TTM
Revenue Growth TTM
PAT Gr TTM
PAT Growth TTM
Peer Comparison
How does CURIS stack up?
Compare up to 10 companies side by side across valuation, profitability, and growth.
CURIS
VS
Quarterly Results
Consolidated
Standalone
Numbers
Percentage
| Quarter | Jun 2025 |
|---|---|
| 20 | |
Growth YoY Revenue Growth YoY% | |
| 15 | |
| 4 | |
OPM OPM% | 21.7 |
| 0 | |
Interest Expense Interest ExpenseCr | 0 |
Depreciation DepreciationCr | 0 |
PBT PBTCr | 4 |
| 1 | |
| 3 | |
Growth YoY PAT Growth YoY% | |
NPM NPM% | 14.7 |
| 4.8 |
Profit & Loss
Consolidated
Standalone
Numbers
Percentage
| Financial Year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
Revenue RevenueCr | 24 | 35 | 36 | 49 |
Growth Revenue Growth% | 49.2 | 0.4 | 38.1 | |
| 20 | 32 | 27 | 40 | |
| 4 | 3 | 8 | 10 | |
OPM OPM% | 15.1 | 9.2 | 23.7 | 19.4 |
| 0 | 0 | 0 | 1 | |
Interest Expense Interest ExpenseCr | 2 | 1 | 1 | 1 |
Depreciation DepreciationCr | 1 | 1 | 1 | 1 |
PBT PBTCr | 1 | 2 | 7 | 8 |
| 1 | 0 | 2 | 2 | |
PAT PATCr | 0 | 1 | 5 | 6 |
Growth PAT Growth% | 149.0 | 336.9 | 14.0 | |
NPM NPM% | 2.1 | 3.5 | 15.1 | 12.4 |
| 9.8 | 24.5 | 107.1 | 10.3 |
Balance Sheet
Consolidated
Standalone
Numbers
Percentage
| Financial Year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
Equity Capital Equity CapitalCr | 1 | 1 | 1 | 6 |
Reserves ReservesCr | -1 | 0 | 5 | 10 |
| 16 | 19 | 19 | 18 | |
| 12 | 10 | 10 | 9 | |
| 27 | 30 | 34 | 43 | |
| 15 | 17 | 22 | 31 | |
| 13 | 12 | 12 | 11 | |
| 27 | 30 | 34 | 43 |
Cash Flow
Consolidated
Standalone
| Financial Year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| 5 | 3 | 0 | -2 | |
| 0 | -1 | 0 | 0 | |
| -5 | -3 | 0 | 2 | |
Net Cash Flow Net Cash FlowCr | 0 | 0 | 0 | 0 |
Free Cash Flow Free Cash FlowCr | 5 | 3 | 0 | |
CFO To PAT CFO To PAT% | 1,004.5 | 272.9 | 5.2 | -28.8 |
CFO To EBITDA CFO To EBITDA% | 138.1 | 102.9 | 3.3 | -18.4 |
Ratios
Consolidated
Standalone
| Financial Year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
Market Cap Market CapitalizationCr | 0 | 0 | 0 | 0 |
Price To Earnings Price To Earnings | 0.0 | 0.0 | 0.0 | 0.0 |
Price To Sales Price To Sales | 0.0 | 0.0 | 0.0 | 0.0 |
Price To Book Price To Book | 0.0 | 0.0 | 0.0 | 0.0 |
EV To EBITDA EV To EBITDA | 4.9 | 4.9 | 2.0 | 1.6 |
GPM GPM% | 41.3 | 30.8 | 43.5 | 35.1 |
OPM OPM% | 15.1 | 9.2 | 23.7 | 19.4 |
NPM NPM% | 2.1 | 3.5 | 15.1 | 12.4 |
ROCE ROCE% | 17.0 | 17.4 | 35.4 | 29.4 |
ROE ROE% | -54.5 | 380.2 | 94.3 | 37.6 |
ROA ROA% | 1.8 | 4.1 | 15.8 | 14.3 |